IMGN - ImmunoGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

9.06

-0.18 (-1.95%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	9.24
Open	9.20
Bid	8.81 x 1000
Ask	9.00 x 800
Day's Range	8.97 - 9.25
52 Week Range	4.80 - 13.41
Volume	1,827,586
Avg. Volume	1,972,874

Market Cap	1.348B
Beta	3.32
PE Ratio (TTM)	N/A
EPS (TTM)	-1.24
Earnings Date	Nov 1, 2018 - Nov 5, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	14.57

Trade prices are not sourced from all markets

All

News

Press Releases

Simply Wall St.3 days ago
Who Owns Most Of ImmunoGen Inc (NASDAQ:IMGN)?
If you want to know who really controls ImmunoGen Inc (NASDAQ:IMGN), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunk ofRead More...
Business Wire26 days ago
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the following presentations by
GlobeNewswire2 months ago
Investor Expectations to Drive Momentum within Ingevity, First Industrial Realty Trust, ImmunoGen, PriceSmart, Pacific Gas & Electric, and Procter & Gamble — Discovering Underlying Factors of Influence
NEW YORK, Aug. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ingevity ...
Business Wire2 months ago
ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Canaccord Genuity Growth Conference. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
Motley Fool2 months ago
ImmunoGen's Investors Play the Waiting Game
Crucial data is expected in the first half of next year.
Thomson Reuters StreetEvents2 months ago
Edited Transcript of IMGN earnings conference call or presentation 27-Jul-18 12:00pm GMT
Q2 2018 ImmunoGen Inc Earnings Call
Zacks2 months ago
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
ImmunoGen (IMGN) reports wider-than-expected loss in Q2. Lower license and milestone fees result in substantial decrease in year-over-year revenues.
Zacks2 months ago
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates
ImmunoGen (IMGN) delivered earnings and revenue surprises of -3.45% and -34.37%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Zacks2 months ago
ImmunoGen (IMGN) Q2 Loss Wider, Revenues Miss
ImmunoGen posted wider-than-expected loss in the second quarter of 2018. Moreover, revenues missed estimates, significantly decreasing year over year.
Business Wire2 months ago
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
Mirvetuximab Soravtansine Granted Fast Track Designation by FDA
ACCESSWIRE2 months ago
ImmunoGen, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 27, 2018 / ImmunoGen, Inc. (NASDAQ: IMGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 27, 2018 at 8:00 AM Eastern Time. To listen ...
Benzinga2 months ago
Immunogen Earnings Preview
Immunogen (NASDAQ: IMGN ) releases its next round of earnings Friday. Here's Benzinga's essential guide to Immunogen's Q2 earnings report. Earnings and Revenue Wall Street expects an EPS loss of 29 cents ...
Zacks2 months ago
What's in Store for ImmunoGen (IMGN) This Earnings Season?
ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, is expected to drive investor interest in the second-quarter earnings call.
Motley Fool2 months ago
Here's Why ImmunoGen Fell 15.1% in June
A secondary offering dilutes investors.
Business Wire2 months ago
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, July 27, 2018 to discuss its second quarter operating results. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
Motley Fool3 months ago
Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
Which of these cancer-focused biotech stocks is the better pick right now?
ACCESSWIRE3 months ago
Free Technical Research on ImmunoGen and Three More Biotech Equities
On Thursday, June 21, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), and ImmunoGen Inc. (NASDAQ: IMGN).
Business Wire3 months ago
ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 2,055,000 shares of ImmunoGen’s common stock at a price of $11.00 per share, before underwriting discounts. The exercise of the option brings the total shares of common stock to be sold by ImmunoGen in the offering to 15,755,000 shares. All of the shares in the offering are to be sold by ImmunoGen.
Zacks3 months ago
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer
With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.
Business Wire3 months ago
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead program, mirvetuximab soravtansine. The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy. “We are pleased the FDA has granted Fast Track designation for mirvetuximab soravtansine,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.
Business Wire3 months ago
ImmunoGen Announces Closing of Public Offering of Common Stock
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $11.00 per share. The gross proceeds to ImmunoGen from the offering (before deducting the underwriting discounts and offering expenses) were $150.7 million. In addition, ImmunoGen has granted the underwriters a 30-day option to purchase up to an additional 2,055,000 shares of common stock at the public offering price, less the underwriting discount.
Motley Fool4 months ago
Here's Why ImmunoGen Inc. Fell 9.2% Today
A secondary offering will dilute investors.
Business Wire4 months ago
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of $11.00 per share, before underwriting discounts. In addition, ImmunoGen has granted the underwriters a 30-day option to purchase up to an additional 2,055,000 shares of common stock at the public offering price, less the underwriting discount. The offering was upsized from the previously announced offering size of 12,000,000 shares of common stock.
Benzinga4 months ago
Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 5) Haemonetics Corporation (NYSE: HAE ) Athersys, Inc. (NASDAQ: ...
Simply Wall St.4 months ago
Has ImmunoGen Inc (NASDAQ:IMGN) Improved Earnings Growth In Recent Times?
Understanding ImmunoGen Inc’s (NASDAQ:IMGN) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check to gainRead More...